American Cyanamid Company

Asana Biosciences, LLC

Wyeth

American Home Products Corporation

Wyeth Holdings Corporation

Pfizer Corporation

Curadev Pharma Pvt Ltd

Elucida Oncology, Inc.

Other

Endo Pharmaceuticals Inc.

Asan Biosciences, LLC

Abs Development 1, Inc.

Ansana Biosciences, LLC

Aranapakam Mudumbai Venkatesan

Jeremy Ian Levin

Roger Astbury Smith

Tarek Suhayl Mansour

Scott Kevin Thompson

Osvaldo Dos Santos

Arie Zask

George Theodore Grosu

Jay Donald Albright

Efren Guillermo Delos Santos

Raghava Reddy Kethiri

Christoph Martin Dehnhardt

Fuk-Wah Sum

Ariamala Gopalsamy

David James Richard

Kevin Joseph Curran

Jeroen Cunera Verheijen

Joshua Aaron Kaplan

Zecheng Chen

Mengxiao Shi

Semiramis Ayral-Kaloustian

Yansong Gu

Ashis K Saha

Tony Priestley

Chandrika Mulakala

Takao Abe

Atul Agarwal

Derek Cecil Cole

James Ming Chen

Bheemashankar A Kulkarni

Sunil Kumar Panigrahi

Vijay Potluri

John P Dusza

Subramanya Hosahalli

Mila T Du

Yang-I Lin

Vincent Premaratna Sandanayaka

Scott K Thompson

Francis Y F Lee

Michael Sotirios Malamas

Richard Eric Mewshaw

Koichi Sato

Purushottam M Dewang

Jamie Marie Davis

Jannie Lea Baker

Mrinal Kundu

Sanjeeva P Reddy

Gurulingappa Hallur

Nicholas James Laping

Rajendra Kristam

Rajesh Devraj

Chandregowda Venkateshappa

Vishnu Basetti

Karunasree Kunta

Gregory P Adams

Hideki Ushirogochi

Satoshi Tamai

Kamal Kishore Kapoor

Monali Banerjee

Sandip Middya

Ritesh Shrivastava

Arjun Surya

Geno J Germano, Jr

Ramesh Mullangi

Mohd Zainuddin

Thomas Courtney Gardinier, Ii

Melik Ziya Türker

Fei Wu

Kai Ma

Feng Chen

Sushil Raina

Dharmendra B Yadav

Veejendra K Yadav

Itsuki Yamamura

Tsuyoshi Takasaki

Ado Mihira

Adam Matthew Gilbert

Ivo L Jirkovsky

Frances Christy Nelson

Joseph Zeldis

Xuemei Du

Magda Asselin

Anita Wai-Yin Chan

Deborah Ann Evrard

Michael William Winkley

Srinivas Nanduri

Gerardo De Francisco

Hosahalli Subramanya

Kristin L Meagher

Henry Strong

Gulnaz Khafizova

Antonia Nikitenko

Kenneth Alfred Martin Kremer

Mallesham Bejugam

Subramanya Hoshalli

Janniee Lea Baker

Matthew Robin O'Dell

Marcy Pamela Jacobson

Baihua Hu

Jeremy I, Levin

The disclosure relates to nanoparticle drug conjugates (NDC) that comprise ultrasmall nanoparticles, folate receptor (FR) targeting ligands, and linker-drug conjugates, and methods of making and using them to treat cancer.

Folate receptor targeted nanoparticle drug conjugates and uses thereof

The present application provides novel heterocyclic compounds and pharmaceutically acceptable salts thereof. Also provided are methods for preparing these compounds. These compounds are useful for inhibiting ERK1/2. By administering to a patient in need a therapeutically effective amount of one or more of the compounds of formula (I), wherein X, Y, Z, J, M, and Rto Rare defined herein, these compounds are effective in treating conditions associated with dysregulation of the RAS/RAF/MEK/ERK pathway. A variety of conditions can be treated using these compounds and include diseases which are characterized by abnormal cellular proliferation. In one embodiment, the disease is cancer.

Heterocyclic inhibitors of ERK1 and ERK2 and their use in the treatment of cancer

The present application provides novel compounds and methods for preparing and using these compounds. In one embodiment, the compounds are of the structure of formula (I), wherein R-Rare defined herein. In a further embodiment, these compounds are useful in method for regulating one or both of the P2Xor P2Xreceptors. In another embodiment, these compounds are useful for treating pain in patients by administering one or more of the compounds to a patient.

P2Xand/or P2Xcompounds and methods

The present application provides novel heterocyclic compounds and pharmaceutically acceptable salts thereof. Also provided are methods for preparing these compounds. These compounds are useful for inhibiting ERK1/2. By administering to a patient in need a therapeutically effective amount of one or more of the compounds of formula (I), wherein X, Y, Z, J, M, and Rto Rare defined herein, these compounds are effective in treating conditions associated with dysregulation of the RAS/RAF/MEK/ERK pathway. A variety of conditions can be treated using these compounds and include diseases which are characterized by abnormal cellular proliferation. In one embodiment, the disease is cancer. 

The present application provides novel pyrimido-pyridazinone compounds and methods for preparing and using these compounds. These compounds are useful in treating inflammation in patients by administering one or more of the compounds to a patient. In one embodiment, the novel pyrimido-pyridazinone compound is of Formula (I) and Rand Rare defined herein. 

Pyrimido-pyridazinone compounds and methods of use thereof

The present application provides novel compounds and methods for preparing and using these compounds. In one embodiment, the compounds are of the structure of formula (I), wherein R-Rare defined herein. In a further embodiment, these compounds are useful in method for regulating one or both of the P2Xor P2Xreceptors. In another embodiment, these compounds are useful for treating pain in patients by administering one or more of the compounds to a patient. In another embodiment, these compounds are useful for treating respiratory dysfunction in patients by administering one or more of the compounds to a patient. 

The present application provides novel compounds and methods for preparing and using these compounds. In one embodiment, the compounds are of the structure of formula (I), wherein R-Rare defined herein. In a further embodiment, these compounds are useful in method for regulating one or both of the P2Xor P2Xreceptors. In another embodiment, these compounds are useful for treating pain in patients by administering one or more of the compounds to a patient. 

[object Object]

The present application provides novel inhibitors of indoleamine 2,3-dioxygenase-1 and/or indoleamine 2,3-dioxygenase-2 and/or tryptophan 2,3-dioxygenase, metabolites thereof, and pharmaceutically acceptable salts or prodrugs thereof. Also provided are methods for preparing these compounds. A therapeutically effective amount of one or more of the compounds of formula (I) is useful in treating diseases resulting from dysregulation of the kynurenine pathway. Compounds of formula (I) act by inhibiting the enzymatic activity or expression of indoleamine 2,3-dioxygenase-1 and/or indoleamine 2,3-dioxygenase-2 and/or tryptophan 2,3-dioxy-genase.

Inhibitors of the kynurenine pathway

Compounds of formula I  and R, R, and Rare defined herein, and pharmaceutically acceptable salts and esters thereof. These compounds inhibit PI3 kinase and mTOR, and may be used to treat diseases mediated by PI3 kinase and mTOR, such as a variety of cancers. Methods for making and using the compounds of this invention are disclosed. Various compositions containing the compounds of this invention are also disclosed.

Triazine compounds as PI3 kinase and mTOR inhibitors

Growing community of inventors

Rego Park, NY, United States of America

Aranapakam Mudumbai Venkatesan